WallStreetZenWallStreetZen

NASDAQ: NLTX
Neoleukin Therapeutics Inc Stock

$0.82+0.01 (+1.23%)
Updated May 26, 2023
NLTX Price
$0.82
Fair Value Price
$1.50
Market Cap
$35.12M
52 Week Low
$0.38
52 Week High
$1.34
P/E
-0.8x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$56.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$45M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NLTX Overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NLTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NLTX ($0.82) is undervalued by 45.19% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NLTX ($0.82) is significantly undervalued by 45.19% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NLTX due diligence checks available for Premium users.

Be the first to know about important NLTX news, forecast changes, insider trades & much more!

NLTX News

Valuation

NLTX fair value

Fair Value of NLTX stock based on Discounted Cash Flow (DCF)
Price
$0.82
Fair Value
$1.50
Undervalued by
45.19%
NLTX ($0.82) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NLTX ($0.82) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NLTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.8x
Industry
14.7x
Market
54.23x

NLTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
1.74x
NLTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NLTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$14.2M
Profit Margin
0%
NLTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$98.5M
Liabilities
$17.1M
Debt to equity
0.21
NLTX's short-term assets ($85.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NLTX's short-term assets ($85.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NLTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NLTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.0M
Investing
$10.7M
Financing
-$66.0k
NLTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NLTX vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
NLTX$35.12M+1.23%-0.80x0.43x
FLGC$34.57M+3.75%N/A0.64x
QLI$36.11M+1.00%33.67x0.68x
RMTI$32.85M+0.42%-1.99x2.62x
COSM$32.18M-4.11%-0.10x0.73x

Neoleukin Therapeutics Stock FAQ

What is Neoleukin Therapeutics's quote symbol?

(NASDAQ: NLTX) Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol NLTX. Neoleukin Therapeutics stock quotes can also be displayed as NASDAQ: NLTX.

If you're new to stock investing, here's how to buy Neoleukin Therapeutics stock.

What is the 52 week high and low for Neoleukin Therapeutics (NASDAQ: NLTX)?

(NASDAQ: NLTX) Neoleukin Therapeutics's 52-week high was $1.34, and its 52-week low was $0.38. It is currently -38.85% from its 52-week high and 118.67% from its 52-week low.

How much is Neoleukin Therapeutics stock worth today?

(NASDAQ: NLTX) Neoleukin Therapeutics currently has 42,828,346 outstanding shares. With Neoleukin Therapeutics stock trading at $0.82 per share, the total value of Neoleukin Therapeutics stock (market capitalization) is $35.12M.

Neoleukin Therapeutics stock was originally listed at a price of $11.95 in Mar 7, 2014. If you had invested in Neoleukin Therapeutics stock at $11.95, your return over the last 9 years would have been -93.14%, for an annualized return of -25.75% (not including any dividends or dividend reinvestments).

How much is Neoleukin Therapeutics's stock price per share?

(NASDAQ: NLTX) Neoleukin Therapeutics stock price per share is $0.82 today (as of May 26, 2023).

What is Neoleukin Therapeutics's Market Cap?

(NASDAQ: NLTX) Neoleukin Therapeutics's market cap is $35.12M, as of May 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Neoleukin Therapeutics's market cap is calculated by multiplying NLTX's current stock price of $0.82 by NLTX's total outstanding shares of 42,828,346.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.